Catherine Gérard

7.9k total citations · 1 hit paper
109 papers, 6.4k citations indexed

About

Catherine Gérard is a scholar working on Molecular Biology, Immunology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Catherine Gérard has authored 109 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Molecular Biology, 27 papers in Immunology and 16 papers in Cellular and Molecular Neuroscience. Recurrent topics in Catherine Gérard's work include Immunotherapy and Immune Responses (18 papers), Thyroid Disorders and Treatments (10 papers) and Food composition and properties (9 papers). Catherine Gérard is often cited by papers focused on Immunotherapy and Immune Responses (18 papers), Thyroid Disorders and Treatments (10 papers) and Food composition and properties (9 papers). Catherine Gérard collaborates with scholars based in Belgium, United States and Canada. Catherine Gérard's co-authors include Thierry Velu, Anne Delvaux, Michel Goldman, Arnaud Marchant, Jason Perret, Marc Parmentier, Anne Lefort, Daniel Abramowicz, Charles J. Doillon and Jake E. Barralet and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Catherine Gérard

108 papers receiving 6.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia.

1993 679 citations Catherine Gérard, Catherine Bruyns et al. profile →

Peers

Countries citing papers authored by Catherine Gérard

Since Specialization

Citations

This map shows the geographic impact of Catherine Gérard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine Gérard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine Gérard more than expected).

Fields of papers citing papers by Catherine Gérard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine Gérard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine Gérard. The network helps show where Catherine Gérard may publish in the future.

Co-authorship network of co-authors of Catherine Gérard

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine Gérard. A scholar is included among the top collaborators of Catherine Gérard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine Gérard. Catherine Gérard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Primary care experience in people with mental health conditions: results from a national patient experience survey 2024 ·New Zealand Medical Journal ·Ruth Cunningham, (unknown), Fiona Imlach, James Stanley, (unknown), (unknown), Debbie Peterson, Catherine Gérard	0
2	Randomized, Open-Label Phase 3 Study Evaluating Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Coadministered with FLU-QIV-HD in Adults Aged ≥ 65 2024 ·Infectious Diseases and Therapy ·Robert Buynak, Kevin D. Cannon, (unknown), John M. Kirby, (unknown), Amit Bhavsar, Catherine Gérard, (unknown), (unknown), (unknown), (unknown), Nadia Meyer	6
3	Finding an Appropriate Mouse Model to Study the Impact of a Treatment for Friedreich Ataxia on the Behavioral Phenotype 2023 ·Genes ·(unknown), Catherine Gérard, (unknown), Nathalie Majeau, (unknown), (unknown), (unknown), (unknown), Jacques P. Tremblay	4
4	Removal of the GAA repeat in the heart of a Friedreich’s ataxia mouse model using CjCas9 2023 ·Gene Therapy ·(unknown), Catherine Gérard, Nathalie Majeau, Jacques P. Tremblay	3
5	Persisting variance in middle ear ventilation tube insertion in Auckland children: why ethnic disparity continues 2022 ·ResearchSpace (University of Auckland) ·(unknown), Randall P. Morton, Catherine Gérard, Lesley Salkeld, Suzanne C. Purdy	3
6	A promising mouse model for Friedreich Ataxia progressing like human patients 2022 ·Behavioural Brain Research ·Catherine Gérard, (unknown), (unknown), Jacques P. Tremblay	14
7	Self-antigen MASH2 combined with the AS15 immunostimulant induces tumor protection in colorectal cancer mouse models 2019 ·PLoS ONE ·Clément R. Rioux, Margie L. Clapper, Harry S. Cooper, Jean Michaud, (unknown), (unknown), (unknown), (unknown), Harvey H. Hensley, Anthony Pilorget, Catherine Gérard	7
8	ADAM10 mediates malignant pleural mesothelioma invasiveness 2019 ·Oncogene ·(unknown), (unknown), Natacha Rocks, (unknown), Catherine Gérard, Christine Gilles, Andreas Ludwig, Bernard Duysinx, Agnès Noël, Didier Cataldo	17
9	Amylolysis of maize mutant starches described with a fractal-like kinetics model 2015 ·Carbohydrate Polymers ·Kamal Kansou, Alain Buléon, Catherine Gérard, Agnès Rolland‐Sabaté	11
10	Multivariate model to characterise relations between maize mutant starches and hydrolysis kinetics 2015 ·Carbohydrate Polymers ·Kamal Kansou, A. Buléon, Catherine Gérard, Agnès Rolland‐Sabaté	11
11	An AAV9 coding for frataxin clearly improved the symptoms and prolonged the life of Friedreich ataxia mouse models 2014 ·Molecular Therapy — Methods & Clinical Development ·Catherine Gérard, Xiao Xiao, Mohammed Filali, (unknown), Marie Arsenault, Jacques Couët, Juan Li, Marie‐Claude Drolet, Pierre Chapdelaine, (unknown), Jacques P. Tremblay	40
12	Estetrol is a weak estrogen antagonizing estradiol-dependent mammary gland proliferation 2014 ·Journal of Endocrinology ·Catherine Gérard, Silvia Blacher, Laudine Communal, Aurélie Courtin, Ekaterine Tskitishvili, Mélanie Mestdagt, Carine Munaut, Agnès Noël, Anne Gompel, Christel Péqueux, Jean Michel Foidart	58
13	Angiogenesis in Calcium Phosphate Scaffolds by Inorganic Copper Ion Release 2009 ·Tissue Engineering Part A ·Jake E. Barralet, Uwe Gbureck, Pamela Habibović, Elke Vorndran, Catherine Gérard, Charles J. Doillon	188
14	Immunotherapy in the landscape of new targeted treatments for non‐small cell lung cancer 2009 ·Molecular Oncology ·Catherine Gérard, C. Debruyne	24
15	Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells 2005 ·Oncogene ·Wenle Xia, Catherine Gérard, Lei-Hua Liu, Nathalie Baudson, (unknown), Neil L. Spector	211
16	Melanoma vaccines: achievements and perspectives. 2003 ·PubMed ·Vincent Brichard, Catherine Gérard	2
17	Designing HER2 vaccines 2002 ·Seminars in Oncology ·Teresa M. Foy, Gary R. Fanger, Susan L. Hand, Catherine Gérard, Claudine Bruck, Martin A. Cheever	29
18	Recombinant human papillomavirus type 16 E7 protein as a model antigen to study the vaccine potential in control and E7 transgenic mice. 2001 ·Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) ·Catherine Gérard, Nathalie Baudson, (unknown), Catherine Ledent, Drew M. Pardoll, Claudine Bruck	11
19	Interleukin‐10 controls interferon‐γ and tumor necrosis factor production during experimental endotoxemia 1994 ·European Journal of Immunology ·Arnaud Marchant, Catherine Bruyns, Peter Vandenabeele, (unknown), Catherine Gérard, Anne Delvaux, Donat De Groote, Daniel Abramowicz, Thierry Velu, Michel Goldman	252
20	Induction of interleukin‐6 and interleukin‐10 by the OKT3 monoclonal antibody: Possible relevance to posttransplant lymphoproliferative disorders 1992 ·Clinical Transplantation ·Michel Goldman, Catherine Gérard, Daniel Abramowicz, Liliane Schandené, Patrick Durez, Luc De Pauw, P Kinnaert, Pierre Vereerstraeten, Thierry Velu	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact